Back

The newest pillar is the most fragile: SGLT2 inhibitors show the lowest 12-month ongoing use among guideline-directed CAD medications in a 15-country European survey

30 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Secondary prevention (2) Secondary Prevention ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Luuk Kieviet

University Medical Center Utrecht, Utrecht (Netherlands (The))

7 More presentations in this session

Presentation thumbnail
The influence of medication costs on secondary cardiovascular prevention decisions: two discrete choice experiments among patients and prescribers
Miss E. Wempe (NL)
Abstract Slides Video
Presentation thumbnail
Low molecular weight heparin for AMI with frailty: short-Term outcomes after early PCI
Professor K. Chen (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
COVID-19 vaccination confers long-term cardioprotection against post-COVID cardiovascular disease: >5-year evidence from causal mediation and target trial emulation
Mr B. Seboka (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
The German lipoprotein apheresis registry - summary of the thirteenth annual report
Doctor A. Vogt (Munich, DE)
Abstract Slides Video
Presentation thumbnail
Prevalence and characteristics of low-dose acetylsalicylic acid intake in the German population: insights from the German National Cohort (NAKO)
Professor J. Neumann (Hamburg, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Secondary prevention (2)

The Event

Event poster

ESC Congress 2026

30 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Adherence and discontinuation of sglt2-inhibitors and glp1-r agonists in patients with type 2 diabetes with and without cardiovascular disease
27 August 2022
thumbnail
Webinar
Translating the 2021 ESC Guidelines on Heart Failure into our daily practice: where do we stand?
22 February 2023
thumbnail
Congress Presentation
Adherence and persistence of optimal medical therapy after myocardial infarction in a low to middle income country
13 March 2021
thumbnail
Congress Presentation
Single pill regimen improves persistence and leads lo better clinical outcome compared to identical multi pill combination. Results of START, a German claims data analysis
30 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources